The independent medical news service

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology.

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

An updated analysis of the ENZAMET trial confirms earlier findings that adding enzalutamide to testosterone suppression provides statistically and clinically meaningful survival improvements in metastatic hormone-sensitive prostate cancer.

Use of 5α-reductase inhibitors is not associated with an increased risk for prostate cancer mortality, and long-term use may indeed reduce the risk, a Swedish population-based study has found.

Find out more about the recommendations on exercise, diet, and weight management here

A meta-analysis has identified a significantly elevated risk for prostate cancer-specific mortality with increases in BMI, waist circumference, and waist-to-hip ratio.

Both traditional hormone therapy and novel androgen receptor signaling inhibitors may be associated with neurocognitive impairment in men with prostate cancer, suggests WHO pharmacovigilance data.

All-cause mortality is significantly reduced in men with prostate cancer receiving adjuvant versus early salvage radiotherapy, particularly if they have four or more positive pelvic lymph nodes, research suggests.

Fewer than one in 10 older men initiating androgen deprivation therapy for localized or regional prostate cancer receive dual-energy x-ray absorptiometry screening to assess bone mineral density, US study findings indicate.

More information about this FDA announcement here

Magnetic resonance imaging screening plus pre-emptive treatment does not significantly reduce clinical spinal cord compression rates in patients with castration-resistant prostate cancer and spinal metastasis, PROMPTS trial data show.

The CADMUS investigators report a “slightly lower” rate of detection of clinically significant prostate cancers with multiparametric ultrasound than multiparametric MRI, but a higher rate of referrals for biopsy.

Read more on this recommendation here

The active autologous dendritic cell-based immunotherapy DCVAC/PCa is well tolerated when combined with docetaxel plus prednisone but does not improve survival in men with metastatic castration-resistant prostate cancer, phase 3 study data show.

Continuing enzalutamide treatment in combination with docetaxel reduces the risk for progression versus placebo plus docetaxel in men with metastatic castration-resistant prostate cancer that progressed during enzalutamide monotherapy, PRESIDE study data show.

ODM-208, a novel nonsteroidal inhibitor of CYP11A1, has demonstrated promising antitumor activity in previously treated patients with metastatic castration-resistant prostate cancer enrolled in the first-in-human CYPIDES study.

Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer, show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

Men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations could benefit from the addition of niraparib to first-line abiraterone acetate plus prednisone, suggest phase 3 trial data.

Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, show data from the phase 3 ARASENS trial.

Olaparib use is associated with reduced pain burden and better preservation of health-related quality of life relative to control treatments in men with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM alterations, research shows.